Sen-Jam Pharmaceutical, a developer of precision remedies to address chronic inflammation and metabolic disorders, announced on Tuesday that it has received ethics approval for a clinical trial of its flagship asset, SJP-001, in Australia.
The trial is intended to assess the the efficacy and safety of SJP-001, an over-the-counter therapeutic targeting metabolic health and relief from overindulgence in food and drink, including its effects on inflammatory pathways.
This milestone paves the way for the product to advance through clinical evaluation, with the trial carried out by Nucleus Network, an Australian early-phase clinical research organisation, and supported by contract research organisation Novotech.
The SJP-001 clinical trial is designed to assess the product's ability to modulate inflammation and improve metabolic outcomes, providing relief from the after effects of dietary overindulgence while supporting long-term metabolic health.
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma